Psoriatic arthritis develops when the immune system mistakenly attacks healthy joint tissue, but the reason it happens involves a chain of factors: genetic vulnerability, an overactive inflammatory cycle, and one or more environmental triggers that set the process in motion. Most people who develop psoriatic arthritis already have psoriasis. Roughly 7% to 26% of people with psoriasis will eventually develop joint involvement, and skin symptoms typically appear about 12 years before joint pain begins.
Genetics Set the Stage
Psoriatic arthritis runs in families. If you have a first-degree relative with the condition, your own risk is significantly higher. Several specific gene variants help explain why. One called HLA-B27, found in about 32.5% of psoriatic arthritis patients compared to roughly 9% of healthy people, carries about 1.6 times the risk of developing the disease. People who carry HLA-B27 also tend to develop more severe joint damage.
Another gene variant, HLA-Cw06, appears to influence timing rather than overall risk. People with this marker tend to develop psoriasis earlier in life and transition from skin-only disease to joint involvement faster. A third variant, HLA-DR7, seems to do the opposite, delaying the progression from psoriasis to arthritis. None of these genes guarantee the disease will develop. They create susceptibility that still requires something else to flip the switch.
The Inflammatory Cycle in Your Joints
The core engine of psoriatic arthritis is a self-reinforcing loop of inflammation driven by immune signaling molecules. The two most important are IL-23 and IL-17. IL-23 is produced by immune cells and acts on specialized T cells that live in the entheses, the spots where tendons and ligaments attach to bone. These T cells respond by releasing large amounts of IL-17, which directly damages joint tissue and triggers new bone formation in places it shouldn’t occur.
What makes this cycle so persistent is a built-in feedback loop. When IL-23 binds to its receptor on a cell, the resulting chemical cascade causes that cell to produce even more IL-23 receptors, amplifying the signal. The immune cells involved aren’t the typical adaptive immune cells that learn to target specific threats. They’re innate-like T cells, including types found in elevated numbers in the joints and blood of people with psoriatic arthritis. These cells can churn out IL-17 continuously, sometimes even without IL-23 prompting them, which helps explain why the inflammation becomes chronic.
Over time, IL-23 and IL-17 together cause two kinds of bone damage: systemic bone loss (similar to osteoporosis) and abnormal new bone growth at the entheses. This combination of erosion and overgrowth is a hallmark of the disease and distinguishes it from rheumatoid arthritis.
Physical Injury as a Trigger
Joint trauma can directly provoke psoriatic arthritis in someone who is genetically predisposed. This is known as the deep Köbner phenomenon, a cousin of the well-known skin Köbner response where a cut or scrape causes a new psoriasis plaque. In the deep version, a fracture, bad contusion, or repetitive mechanical stress on a joint triggers internal inflammation that spreads from the damaged tissue into the surrounding joint lining.
The mechanism works through two pathways. First, tissue damage floods the area with inflammatory molecules like TNF-alpha and IL-17, which spill into the adjacent synovial tissue and cause swelling. Second, the trauma activates nerve endings that release neuropeptides, chemical signals that promote tissue proliferation and the breakdown of cartilage. In someone whose entheses already have subtle, pre-existing microstructural changes from their underlying immune condition, this combination of nerve-driven and immune-driven inflammation can tip the balance into full clinical arthritis.
Obesity and Chronic Low-Grade Inflammation
Carrying excess body fat doesn’t just increase mechanical stress on joints. Adipose tissue functions as an active hormonal organ, constantly releasing inflammatory signaling molecules. One of the most important is leptin, a hormone produced in proportion to fat mass. Leptin stimulates production of the same pro-inflammatory molecules involved in psoriatic arthritis, including IL-17, TNF-alpha, and IL-6, while simultaneously suppressing anti-inflammatory signals. Another fat-derived hormone, adiponectin, normally helps calm inflammation, but its protective effects are reduced in people with obesity.
Beyond these hormones, fat tissue directly releases TNF-alpha and IL-6 into the bloodstream, maintaining a state of chronic, low-level inflammation throughout the body. Research in animal models has shown that a specific stress-response pathway in fat cells is overactive in obese individuals, further fueling immune reactions. For someone already genetically primed for psoriatic arthritis, this persistent inflammatory background can accelerate the transition from psoriasis alone to psoriasis plus joint disease.
Gut Bacteria and Immune Activation
The balance of bacteria in your gut plays a role in regulating your immune system, and that balance is disrupted in many people with psoriatic arthritis. The pattern involves a decrease in beneficial bacterial species and an increase in potentially harmful ones. This imbalance weakens the intestinal barrier, allowing bacterial products to leak into the bloodstream and trigger immune responses far from the gut itself. This connection between the gut and joints is part of the reason psoriatic arthritis, inflammatory bowel disease, and psoriasis frequently overlap in the same patients, all linked by IL-23-driven inflammation.
Infections That Kick-Start the Process
Certain infections appear capable of triggering psoriatic arthritis in susceptible people. Streptococcal throat infections are the best-documented example. In case reports, patients developed acute psoriatic spondyloarthritis (a form affecting the spine) within 7 to 10 days of a confirmed strep infection, and these cases progressed to chronic disease. The infection itself doesn’t cause psoriatic arthritis, but it likely activates an immune response that, in a genetically vulnerable person, misfires and targets joint tissue.
Epigenetic Changes That Alter Immune Cells
Even among people with similar genetic backgrounds, something determines who progresses from skin psoriasis to joint disease and who doesn’t. Part of the answer lies in epigenetics: chemical modifications to DNA that change how genes behave without altering the genetic code itself. Researchers have identified nearly 2,500 locations across the genome where DNA methylation patterns differ between people with skin-only psoriasis and those with psoriatic arthritis.
These differences are concentrated in a specific type of immune cell (CD8+ T cells) and affect pathways related to cartilage development and tissue remodeling. Notably, methylation patterns tied to TNF and IL-17 signaling correlate inversely with disease severity: the more active the disease, the more these genes are switched on. Treatment with immune-targeting therapies can partially reverse these methylation changes, suggesting they’re not permanent alterations but dynamic marks that respond to the inflammatory environment.
How These Factors Work Together
Psoriatic arthritis rarely has a single cause. The typical path involves genetic susceptibility that creates an immune system prone to overreaction, environmental factors like obesity or gut imbalance that maintain a constant low hum of inflammation, and a triggering event, whether an infection, a joint injury, or accumulated mechanical stress, that tips the immune system into attacking joint tissue. Once the IL-23/IL-17 cycle establishes itself, its self-amplifying nature makes the inflammation self-sustaining.
The long gap between psoriasis onset and joint symptoms, averaging 12 years, likely reflects this slow buildup. Subclinical inflammation at the entheses may simmer for years before crossing a threshold into pain, swelling, and visible joint damage. People with psoriasis who are overweight, have nail pitting, experience scalp involvement, or carry HLA-B27 face higher odds of eventually developing joint disease.